Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 288 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pleural Malignancies Clear all
Completed Phase 1 Interventional

Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural Malignancy

NCT01998529
View directory record Official record
Conditions
Lung Cancer
Interventions
Cisplatin, Amifostine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
3 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 23, 2026, 10:24 AM EDT
Completed Phase 1 Interventional

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

NCT04040231
View directory record Official record
Conditions
Mesothelioma, Pleural Mesothelioma, Wilms Tumor
Interventions
Galinpepimut-S, Nivolumab, Sargramostim
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 23, 2026, 10:24 AM EDT
Completed Phase 2 Interventional Results available

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

NCT00365053
View directory record Official record
Conditions
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
Interventions
belinostat, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 23, 2026, 10:24 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy

NCT01580618
View directory record Official record
Conditions
Pleural Effusion
Interventions
normal saline, TNK (Tenecteplase)
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 23, 2026, 10:24 AM EDT
Not yet recruiting Phase 2 Interventional

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

NCT05425576
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
OT-101
Drug
Lead sponsor
Oncotelic Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 23, 2026, 10:24 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

NCT00126581
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Malignant Pericardial Effusion, Malignant Pleural Effusion, Minimally Invasive Lung Adenocarcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Carboplatin, Erlotinib, Erlotinib Hydrochloride, Paclitaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
96
States / cities
Castro Valley, California • Emeryville, California • Fremont, California + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 23, 2026, 10:24 AM EDT
Recruiting No phase listed Observational

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

NCT00242723
View directory record Official record
Conditions
Thoracic Cancers, Malignant Pleural Mesotheliomas NOS, Lung Cancer NOS, Esophageal Cancers NOS, Cancers of Non Thoracic Origin With Metastases to the Lungs or Pleura, Thoracic Malignancies
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 120 Years
Enrollment
1,559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 10:24 AM EDT
Completed Phase 2 Interventional

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

NCT00039182
View directory record Official record
Conditions
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
Interventions
erlotinib hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 23, 2026, 10:24 AM EDT
Completed Phase 2 Interventional

MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer

NCT00799240
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Arm A: Pemetrexed Cisplatin, Arm B Pemetrexed, Cisplatin and MK-0646
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Hutchinson, Kansas • Kansas City, Kansas • Topeka, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2014 · Synced Oct 23, 2026, 10:24 AM EDT
Completed Phase 1 Interventional

Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma

NCT00571298
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Extrapleural pneumonectomy (EPP), Cisplatin, gemcitabine, amifostine, sodium thiosulfate, Pleurectomy/Decortication
Procedure · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 23, 2026, 10:24 AM EDT
Completed Phase 1 Interventional

Intrapleural Gene Transfer for Pleural Mesothelioma

NCT01212367
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
SCH 721015
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Oct 23, 2026, 10:24 AM EDT
Recruiting Phase 1 Interventional

Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer

NCT06016179
View directory record Official record
Conditions
Malignant Pleural Effusion, Malignant Ascites
Interventions
Tocilizumab
Drug
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 23, 2026, 10:24 AM EDT
Completed Phase 2 Interventional Results available

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

NCT01112293
View directory record Official record
Conditions
Pleural Malignant Mesothelioma
Interventions
GC1008
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 23, 2026, 10:24 AM EDT
Terminated Early Phase 1 Interventional

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients

NCT04213794
View directory record Official record
Conditions
Malignant Abdominal Neoplasm, Malignant Pelvic Neoplasm, Recurrent Colon Carcinoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Gastric Carcinoma, Recurrent Liposarcoma, Recurrent Malignant Mesothelioma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Rectal Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Sarcoma, Refractory Colon Carcinoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Fallopian Tube Carcinoma, Refractory Gastric Carcinoma, Refractory Liposarcoma, Refractory Malignant Mesothelioma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma, Refractory Rectal Carcinoma, Refractory Rhabdomyosarcoma, Refractory Sarcoma, Resectable Liposarcoma, Resectable Malignant Mesothelioma, Resectable Sarcoma
Interventions
Cisplatin, Cytoreductive Surgery, Doxorubicin, Hyperthermic Intraperitoneal Chemotherapy, Sodium Thiosulfate, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Biospecimen Collection
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year to 25 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 23, 2026, 10:24 AM EDT
Terminated Phase 1 Interventional

Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum

NCT01313429
View directory record Official record
Conditions
Sarcoma, Melanoma, Epithelial Malignancies, Pleural Malignancies
Interventions
Cyclophosphamide, Allogenic tumor Cell Vaccine (K562), Celecoxib
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 23, 2026, 10:24 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

NCT03228537
View directory record Official record
Conditions
Biphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IB Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage II Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage III Pleural Diffuse Malignant Mesothelioma AJCC v7
Interventions
Atezolizumab, Cisplatin, Extrapleural Pneumonectomy, Pemetrexed Disodium, Pleurectomy, Radiation Therapy
Drug · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
174
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 121 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 10:24 AM EDT
Not listed Phase 1 Interventional

Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma

NCT00006216
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
PA-1-STK ovarian carcinoma vaccine, ganciclovir
Biological · Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 23, 2026, 10:24 AM EDT
Withdrawn No phase listed Observational

Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer

NCT00897143
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer
Interventions
microarray analysis, mutation analysis, flow cytometry, immunologic technique
Genetic · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 23, 2026, 10:24 AM EDT
Completed No phase listed Observational

Clinical and Histopathologic Characteristics of BAP1 Mutations

NCT01773655
View directory record Official record
Conditions
Malignant Pleural Mesothelioma (MPM), Choroidal Nevus, Primary Uveal Melanoma (UM), Metastatic Uveal Melanoma (UM), Renal Cell Carcinoma, Cholangiocarcinoma
Interventions
tumor specimens
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 23, 2026, 10:24 AM EDT
Active, not recruiting Phase 3 Interventional

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

NCT06097728
View directory record Official record
Conditions
Unresectable Pleural Mesothelioma
Interventions
Volrustomig, Pemetrexed, Carboplatin, Cisplatin, Nivolumab, Ipilimumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
863 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
14
States / cities
Santa Rosa, California • Aurora, Colorado • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 10:24 AM EDT
Terminated Phase 1Phase 2 Interventional

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

NCT05500508
View directory record Official record
Conditions
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
Interventions
AMXT1501, DFMO
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 23, 2026, 10:24 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Thromboelastography During Surgery for Malignant Pleural Mesothelioma

NCT01912547
View directory record Official record
Conditions
Coagulopathy, Mesothelioma
Interventions
Blood draw for TEG analysis
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2015 · Synced Oct 23, 2026, 10:24 AM EDT
Completed Phase 2 Interventional Results available

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

NCT02610140
View directory record Official record
Conditions
Mesothelioma
Interventions
Anetumab ravtansine (BAY94-9343), Vinorelbine
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
15
States / cities
La Jolla, California • Aurora, Colorado • Norwich, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 23, 2026, 10:24 AM EDT
Recruiting No phase listed Observational

Study of the Disease Process of Lymphangioleiomyomatosis

NCT00001465
View directory record Official record
Conditions
Lung Disease, Pneumothorax, Tuberous Sclerosis, Lymphangioleiomyomatosis
Interventions
Toshibia Aquilion One CT
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
16 Years to 100 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 10:24 AM EDT